World Health Organization. Diagnostic criteria for research. Geneva: World Health Organization; 1993. The ICD-10 classification of mental and behavioural disorders.

Wepfer J.J. Observationes anatomicae, ex cadaveribus eorum, quos sustulit apoplexia. Cum exercitatione de ejus loco affecto. Schaffhausen, Joh Caspari Suteri; 1658.

Kraepelin E. Psychiatrie: ein Lehrbuch fьr Studierende und Дrzte. Leipzig: Barth;1910. 684 p.

Wolters F.J., Ikram M.A. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol. 2019;39(8):1542–49. doi: 10.1161/ATVBAHA.119.311908..
DOI: 10.1161/ATVBAHA.119.311908

Akhter F., Persaud A., Zaokari Y., et al. Vascular Dementia and Underlying Sex Differences.Front Aging Neurosci. 2021;13:720715. doi: 10.3389/fnagi.2021.720715..
DOI: 10.3389/fnagi.2021.720715

Azarpazhooh M.R., Avan A., Cipriano L.E., et al. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimer’s Dement. 2018;14:148–56. doi: 10.1016/j.jalz.2017.07.755..
DOI: 10.1016/j.jalz.2017.07.755

2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024;20(5):3708–821. doi: 10.1002/alz.13809..
DOI: 10.1002/alz.13809

Pendlebury S.T., Rothwell P.M. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: Analysis of the population-based Oxford Vascular Study. Lancet Neurol. 2019;18:248–58. doi: 10.1016/S1474-4422(18)30442-3..
DOI: 10.1016/S1474-4422(18)30442-3

Livingston G., Huntley J., Sommerlad A., et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396(10248):413–46. doi: 10.1016/S0140-6736(20)30367-6..
DOI: 10.1016/S0140-6736(20)30367-6

Diniz B.S., Butters M.A., Albert S.M., et al. Late-life depression and risk of vascular dementia and Alzheimer’s disease: Systematic review and meta-analysis of community-based cohort studies. Br. J. Psychiatry. 2013;202:329–35. doi: 10.1192/bjp.bp.112.118307..
DOI: 10.1192/bjp.bp.112.118307

Iadecola C. The Pathobiology of Vascular Dementia. Neuron. 2013;80:844–66. doi: 10.1016/j.neuron.2013.10.008..
DOI: 10.1016/j.neuron.2013.10.008

Liu Q., Zhu Z., Teipel S.J., Yang J., et al. White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia. Front. Aging Neurosci. 2017;9:47. doi: 10.3389/fnagi.2017.00047..
DOI: 10.3389/fnagi.2017.00047

Erkinjuntti T. Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia. 1994;5(3-4):189–92. doi: 10.1159/000106721..
DOI: 10.1159/000106721

Ampil E.R., Ong P.A., Krespi Y., Yang Y.H. A review of SaiLuoTong (MLC-SLT) development in vascular cognitive impairment and dementia. Front Pharmacol. 2024;15:1343820. doi: 10.3389/fphar.2024.1343820..
DOI: 10.3389/fphar.2024.1343820

Rundek T., Tolea M., Ariko T., et al. Vascular Cognitive Impairment (VCI). Neurotherapeutics. 2022;19(1):68–88. doi: 10.1007/s13311-021-01170-y..
DOI: 10.1007/s13311-021-01170-y

Skrobot O.A., Black S.E., Chen C., et al. VICCCS group; Ben-Shlomo Y., Passmore A.P., Love S., Kehoe P.G. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2018;14(3):280–92. doi: 10.1016/j.jalz.2017.09.007..
DOI: 10.1016/j.jalz.2017.09.007

Badji A., Youwakim J., Cooper A., et al. Vascular cognitive impairment - Past, present, and future challenges. Ageing Res Rev. 2023;90:102042. doi: 10.1016/j.arr.2023.102042..
DOI: 10.1016/j.arr.2023.102042

MacDonald M.E., Pike G.B. MRI of healthy brain aging: a review. NMR Biomed 2021;34:e4564. doi: 10.1002/nbm.4564..
DOI: 10.1002/nbm.4564

Heiss W.D., Rosenberg G.A., Thiel A., et al. Neuroimaging in vascular cognitive impairment: a state-of-the-art review. BMC Med. 2016;14(1):174. doi: 10.1186/s12916-016-0725-0..
DOI: 10.1186/s12916-016-0725-0

Heiss W.D. The Additional Value of PET in the Assessment of Cerebral Small Vessel Disease. J Nucl Med. 2018;59(11):1660–64. doi: 10.2967/jnumed.118.21427..
DOI: 10.2967/jnumed.118.21427

Frantellizzi V., Pani A., Ricci M., et al. Neuroimaging in Vascular Cognitive Impairment and Dementia: A Systematic Review. J Alzheimers Dis. 2020;73(4):1279–94. doi: 10.3233/JAD-191046..
DOI: 10.3233/JAD-191046

Hamilton O.K.L., Backhouse E.V., Janssen E., et al. Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta-analysis. Alzheimers Dement. 2021;17(4):665–85. doi: 10.1002/alz.12221..
DOI: 10.1002/alz.12221

Bir S.C., Khan M.W., Javalkar V., et al. Emerging Concepts in Vascular Dementia: A Review. J Stroke Cerebrovasc Dis. 2021;30(8):105864. doi: 10.1016/j.jstrokecerebrovasdis.2021..
DOI: 10.1016/j.jstrokecerebrovasdis.2021

Gupta M., Dasgupta A., Khwaja G.A., et al. Behavioural and psychological symptoms in poststroke vascular cognitive impairment. Behav Neurol. 2014;2014:430128. doi: 10.1155/2014/430128..
DOI: 10.1155/2014/430128

Santos M.A.O., Bezerra L.S., Correia C.D.C., Bruscky I.S. Neuropsychiatric symptoms in vascular dementia: Epidemiologic and clinical aspects. Dement Neuropsychol. 2018;12(1):40–4. doi: 10.1590/1980-57642018dn12-010006..
DOI: 10.1590/1980-57642018dn12-010006

Sun M.K. Potential therapeutics for vascular cognitive impairment and dementia. Curr Neuropharmacol. 2018;16(7):1036–44. doi: 10.2174/1570159X15666171016164734..
DOI: 10.2174/1570159X15666171016164734

Yu W., Li Y., Hu J., et al. A study on the pathogenesis of vascular cognitive impairment and dementia: the chronic cerebral hypoperfusion hypothesis. J Clin Med. 2022;11(16):4742. doi: 10.3390/jcm11164742..
DOI: 10.3390/jcm11164742

Ткачева О.Н., Мхитарян Э.А., Колыхалов И.В. и др. Лечение когнитивных, психических и поведенческих нарушений у пациентов с сосудистой деменцией: результаты многоцентрового рандомизированного двойного слепого плацебо-контролируемого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(7):41–9. [Tkacheva O.N., Mkhitaryan E.A., Kolykhalov I.V., et al. Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(7):41–9. (In Russ.)]. doi: 10.17116/jnevro202312307141..
DOI: 10.17116/jnevro202312307141

Battle C.E., Abdul-Rahim A.H., Shenkin S.D., et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst. Rev. 2021;2(2):CD013306. doi: 10.1002/14651858.CD013306..
DOI: 10.1002/14651858.CD013306

Baskys A., Cheng J. Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives. Experimental Gerontol. 2012;47:887–91. doi: 10.1016/j.exger.2012.07.002..
DOI: 10.1016/j.exger.2012.07.002

Smith E.E., Barber P., Field T.S., Ganesh A., et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD) 5: Guidelines for management of vascular cognitive impairment. Alzheimer’s Dement. 2020;6:e12056. doi: 10.1002/trc2.12056..
DOI: 10.1002/trc2.12056

Alam S., Lingenfelter K.S., Bender A.M., Lindsley C.W. Classics in Chemical Neuroscience: Memantine. ACS Chem Neurosci. 2017;8:1823–29. doi: 10.1021/acschemneuro.7b00270..
DOI: 10.1021/acschemneuro.7b00270

Folch J., Busquets O., Ettcheto M., et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J Alzheimers Dis. 2018;62(3):1223–40. doi: 10.3233/JAD-170672..
DOI: 10.3233/JAD-170672

Parsons C.G., Gilling K.E., Jatzke C. Memantine does not show intracellular block of the NMDA receptor channel. Eur J Pharmacol. 2008;587(1–3):99–103. doi: 10.1016/j.ejphar.2008.03.053..
DOI: 10.1016/j.ejphar.2008.03.053

Farooq M.U., Min J., Goshgarian C., Gorelick P.B. Pharmacotherapy for vascular cognitive impairment. CNS Treatments. 2017;31:759–76. doi: 10.1007/s40263-017-0459-3..
DOI: 10.1007/s40263-017-0459-3

Jin B.R., Liu H.Y. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.Neural Regen Res. 2019;14(5):805–16. doi: 10.4103/1673-5374.249228..
DOI: 10.4103/1673-5374.249228

Orgogozo J.M., Rigaud A.S., Stoffler A., et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834–39.doi: 10.1161/01.str.0000020094.08790.49..
DOI: 10.1161/01.str.0000020094.08790.49

Wilcock G., Mцbius H.J., Stцffler A. MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297–305. doi: 10.1097/00004850-200211000-00005..
DOI: 10.1097/00004850-200211000-00005

Любов Е.Б. и группа исследователей. Клинико-функциональный и ресурсосберегающий эффекты лечения акатинолом деменции альцгеймеровского типа и сосудистой деменции. Социальная и клиническая психиатрия. 2009;1:61–73. [Lyubov E.B. et al. Clinical, pharmacoepidemiological and pharmacoecomonic aspects of use of akatinol (memantine) in dementia. Social’naya i klinicheskaya psihiatriya. 2009;1:61–73. (In Russ.)].

Гаврилова С.И., Колыхалов И.В., Михайлова Н.М. и др. Многоцентровое открытое сравнительное рандомизированное исследование эффективности и безопасности применения препарата Акатинол Мемантин, 20 мг (однократный прием) в сравнении с препаратом Акатинол Мемантин, 10 мг (двукратный прием) у пациентов с сосудистой деменцией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(2):69–77. [Gavrilova S.I., Kolykhalov I.V., Mikhaylova N.M., et al. Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(2):69–77. (In Russ.)]. doi: 10.17116/jnevro20241..
DOI: 10.17116/jnevro20241